modelPerphenazine
Extends from Pharmacolibrary.Drugs.ATC.N.N05AB03.
Information
| name: | Perphenazine | |
| ATC code: | N05AB03 | route: | oral |
| compartments: | 1 | |
| dosage: | 8 | mg |
| volume of distribution: | 10 | L |
| clearance: | 20 | L/h |
| other parameters in model implementation | ||
Perphenazine is a typical antipsychotic drug from the phenothiazine class used primarily in the treatment of schizophrenia and severe nausea or vomiting. While widely used in the past, its use has declined in many countries with the advent of atypical antipsychotics, but it remains approved and available in several regions.
Pharmacokinetics
Pharmacokinetic parameters estimated for an adult population based on available summary literature; no direct individual-based pharmacokinetic modeling publications identified.
References
Jerling, M, et al., & Sjöqvist, F (1996). The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clinical pharmacology and therapeutics 59(4) 423–428. DOI:10.1016/S0009-9236(96)90111-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8612387
Zang, YN, et al., & Ruan, CJ (2021). The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. European journal of drug metabolism and pharmacokinetics 46(3) 353–371. DOI:10.1007/s13318-021-00673-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33677821
Fitzgerald, PB (2010). BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia. Current opinion in investigational drugs (London, England : 2000) 11(1) 92–100. PUBMED:https://pubmed.ncbi.nlm.nih.gov/20047163
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)